PG4KDS: A model for the clinical implementation of pre‐emptive pharmacogenetics
暂无分享,去创建一个
Ching-Hon Pui | Ulrich Broeckel | Mark R Wilkinson | James M Hoffman | Wenjian Yang | M. Relling | C. Pui | W. Evans | U. Broeckel | Wenjian Yang | M. Wilkinson | J. Hoffman | S. Howard | D. Baker | K. Crews | C. Haidar | N. Kornegay | Mary V Relling | William E Evans | A. Gaur | Scott C Howard | Aditya H Gaur | Kristine R Crews | Cyrine E Haidar | Donald K Baker | Nancy M Kornegay | Ulrike M Reiss | U. Reiss | J. M. Hoffman
[1] C. Pui,et al. A Health‐Care System Perspective on Implementing Genomic Medicine: Pediatric Acute Lymphoblastic Leukemia as a Paradigm , 2013, Clinical pharmacology and therapeutics.
[2] Frances P Lawrenz,et al. Managing Incidental Findings in Human Subjects Research: Analysis and Recommendations , 2008, The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics.
[3] M. Relling,et al. Concordance of DMET Plus Genotyping Results With Those of Orthogonal Genotyping Methods , 2012, Clinical pharmacology and therapeutics.
[4] H. Guchelaar,et al. Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.
[5] L Gong,et al. The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy , 2012, Clinical pharmacology and therapeutics.
[6] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update , 2013, Clinical pharmacology and therapeutics.
[7] J. Mega,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update , 2013, Clinical pharmacology and therapeutics.
[8] M. Relling,et al. Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.
[9] E. Clayton,et al. Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project , 2012, Clinical pharmacology and therapeutics.
[10] E. Clayton. Incidental Findings in Genetics Research Using Archived DNA , 2008, The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics.
[11] T. Skaar,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update , 2014 .
[12] Urs A. Meyer,et al. Pharmacogenetics – five decades of therapeutic lessons from genetic diversity , 2004, Nature Reviews Genetics.
[13] Richard M Weinshilboum,et al. Genomics and drug response. , 2011, The New England journal of medicine.
[14] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype , 2012, Clinical pharmacology and therapeutics.
[15] R B Altman,et al. Challenges in the Pharmacogenomic Annotation of Whole Genomes , 2013, Clinical pharmacology and therapeutics.
[16] Howard L McLeod,et al. Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.
[17] Marc S. Williams,et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.
[18] R. Altman,et al. Personal Genomic Measurements: The Opportunity for Information Integration , 2013, Clinical pharmacology and therapeutics.
[19] G. Ginsburg,et al. Institutional Profile: A hub for bench-to-bedside pharmacogenomic-based research , 2011 .
[20] T. Klein,et al. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.
[21] D. Venzon,et al. Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. , 2010, Pharmacogenomics.
[22] M. Relling,et al. Thiopurine methyltransferase in acute lymphoblastic leukemia. , 2006, Blood.
[23] E. Green,et al. Genomics Reaches the Clinic: From Basic Discoveries to Clinical Impact , 2011, Cell.
[24] Kristin A. Maloney,et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real‐World Implementation , 2013, Clinical pharmacology and therapeutics.
[25] M. Relling,et al. Development and use of active clinical decision support for preemptive pharmacogenomics , 2013, Journal of the American Medical Informatics Association : JAMIA.
[26] M R Wilkinson,et al. A Clinician‐Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record , 2012, Clinical pharmacology and therapeutics.
[27] M. Relling,et al. Clinical Implementation of Pharmacogenetics: More than One Gene at a Time , 2013, Clinical pharmacology and therapeutics.
[28] William E. Evans,et al. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy , 2006, Nature Reviews Cancer.
[29] M. Relling,et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. , 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[30] K. Sangkuhl,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy , 2011, Clinical pharmacology and therapeutics.
[31] L. Garrison,et al. A Formal Risk-benefit Framework for Genomic Tests: Facilitating the Appropriate Translation of Genomics into Clinical Practice , 2022 .
[32] M. Guyer,et al. Charting a course for genomic medicine from base pairs to bedside , 2011, Nature.